Fixed RNA Profiling Kit stabilizes human
samples at collection; Nuclei Isolation Kit simplifies frozen
sample analysis
PLEASANTON, Calif., April 14,
2022 /PRNewswire/ -- 10x Genomics (Nasdaq:
TXG), a life sciences leader focused on mastering biology to
advance human health, today announced the commercial availability
of two new products designed to improve sample preparation workflow
and broaden the adoption of the company's leading Chromium platform
for single cell analysis: Fixed RNA Profiling and Nuclei Isolation
Kits. Together, these kits will enable easier single cell multiomic
analysis of fragile human tissue samples and make frozen sample
analysis, which is currently costly and time consuming, more
accessible.
![10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) 10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)](https://mma.prnewswire.com/media/1700607/10x_Genomics_Logo.jpg)
"Single cell analysis is revolutionizing biomedical research and
transforming the future of health and medicine," said Ben Hindson, Co-founder and Chief Scientific
Officer for 10x Genomics. "We believe the new capabilities we're
announcing today will bring the future forward and help realize the
expanding potential of single cell analysis by removing obstacles
to larger scale, multi-site studies and enabling broader adoption
of single cell methods in translational research."
Hindson continued, "These new kits are among the first of
several new products planned across our Chromium, Visium and Xenium
platforms this year. We're working hard to make 2022 the most
exciting year of product launches in our history."
Fixed RNA Profiling Kit
Currently, single cell researchers must intricately plan and
coordinate their experiments so as to maintain cell viability of
live samples, working quickly from sample collection through to
processing.
"A key limiting factor of RNA sequencing is the availability of
resources at the time of collection, which can occur outside normal
working hours due to various reasons," said Luciano Martelotto,
Ph.D., Associate Professor, Single Cell and Spatial Technologies
Lab at the University of Adelaide.
"The Fixed RNA Profiling kit allows fixation of cells immediately
after single cell suspension preparation, making it possible to
store cells for future experiments without relying on
cryopreservation, which can distort the cell composition of the
original sample."
The Fixed RNA Profiling Kit enables researchers to fix their
tissue at the time of collection, store it, and proceed to a single
cell workflow at a time and place of their choosing. The kit, which
combines entirely new chemistry and chip with a formaldehyde
fixation to preserve the biological state at the point of
collection, enables batching of samples for maximum study
flexibility. In addition, the kit provides improved sensitivity and
more efficient sequencing as well as built-in sample multiplexing
capabilities. With the ability to probe cell surface protein
expression for multiomic studies, the Fixed RNA Profiling Kit is
compatible with any human single cell suspension.
"Single cell measurements have been transformative to our
understanding of human health and disease, but the research
potential has been hampered by cost," said Peter Skene, Ph.D., Director of Molecular
Biology & Biochemistry at the Allen Institute for Immunology.
"New multiplexed technologies promise to significantly reduce the
cost and boost global research. By locking the cell state, fixed
cell measurements will allow unprecedented insight into drug
mechanisms, including intracellular protein measurements. Taken
together, the new era of single cell research will be a paradigm
shift phase in translational research."
Nuclei Isolation Kit
For researchers with unsequenced archival tissue, 10x Genomics
developed the Nuclei Isolation Kit to unlock frozen tissues for
single cell analysis, answering a major customer request. Standard
methods for nuclei isolation from frozen tissue include complex,
low-throughput and time-consuming protocols, expensive instruments
for sorting and debris removal, and the need to optimize workflows
for each tissue. The Nuclei Isolation Kit is a simple, scalable
product designed to remove those barriers. With an hour of time and
a benchtop centrifuge, the kit enables the generation of high
quality nuclei suspensions from a wide range of frozen samples on
Chromium, without any expensive instruments or complicated
pipetting.
The Fixed RNA Profiling Kit is available now for pre-order,
while the Nuclei Isolation Kit is expected to open for pre-order
soon. Both kits are expected to begin shipping in mid-May.
In addition, earlier this month, 10x Genomics began shipping both
5' CRISPR, an extension to Single Cell Immune Profiling to make
large scale, functional genomics studies quicker and easier; and
ATAC v2, an update to the Single Cell ATAC-seq workflow to boost
sensitivity while increasing discovery power and reducing
costs.
About 10x Genomics
10x Genomics is a life science technology company building
products to interrogate, understand and master biology to advance
human health. The company's integrated solutions include
instruments, consumables and software for analyzing biological
systems at a resolution and scale that matches the complexity of
biology. 10x Genomics products have been adopted by researchers
around the world including in all of the top 100 global research
institutions as ranked by Nature in 2020 based on publications and
all of the top 20 global pharmaceutical companies by 2020 research
and development spend and have been cited in over 3,300 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
1,300 issued patents and patent applications.
Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which fall under the "safe harbor" provisions of those
sections. All statements, other than statements of historical
facts, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as "may," "might," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplate," "believe," "estimate,"
"predict," "potential" or "continue" or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s ("10x
Genomics") product performance, configuration, capabilities and
adoption. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors, including the potential impact of the COVID-19 pandemic.
Other risks and uncertainties that could affect 10x Genomics'
financial and operating results and cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release include those discussed under the
captions "Risk Factors" and "Management's Discussion and Analysis
of Financial Condition and Results of Operations" and elsewhere in
the documents 10x Genomics files with the Securities and Exchange
Commission (the "SEC") from time to time. Although 10x Genomics
believes that the expectations reflected in the forward-looking
statements are reasonable, it cannot provide any assurance that
these expectations will prove to be correct nor can it guarantee
that the future results, levels of activity, performance and events
and circumstances reflected in the forward-looking statements will
be achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the SEC, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
Media Contact:
media@10xgenomics.com
Investor Relations
Contact:
investors@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-two-new-products-to-unlock-wider-range-of-samples-for-single-cell-analysis-on-chromium-301525562.html
SOURCE 10x Genomics, Inc.